Oxcarbazepine (All indications)

Digestive system anomalies

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S12831
R48323		 Thomas (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2021 Gastro-intestinal malformations 1st trimester prospective cohort exposed to other treatment, sick excluded Adjustment: No 0.70 [0.01;35.99] C
excluded (control group) 		0/71   0/50 0 71
ref
S12833
R48335		 Thomas (Oxcarbazepine) (Controls unexposed, sick), 2021 Gastro-intestinal malformations 1st trimester prospective cohort unexposed, sick Adjustment: No 1.60 [0.06;39.70] C 0/71   1/340 1 71
ref
S9062
R30938		 Morrow (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2006 Gastrointestinal tract defects 1st trimester prospective cohort exposed to other treatment, sick Adjustment: No 14.14 [0.66;302.33] C 0/7   3/647 3 7
ref
Total 2 studies 5.01 [0.55;45.94] 4 78
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Thomas (Oxcarbazepine) (Controls unexposed, sick), 2021Thomas, 2021 1 1.60[0.06; 39.70]17148%ROB confusion: seriousROB selection: moderateROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate Morrow (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2006Morrow, 2006 2 14.14[0.66; 302.33]3752%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (2 studies) I2 = 0% 5.01[0.55; 45.94]4780.550.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Oxcarbazepine) (Controls unexposed, sick; 2: Oxcarbazepine) (Controls exposed to Lamotrigine, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 5.01[0.55; 45.94]4780%NAThomas (Oxcarbazepine) (Controls unexposed, sick), 2021 Morrow (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2006 2 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 1.60[0.06; 39.70]171 -NAThomas (Oxcarbazepine) (Controls unexposed, sick), 2021 1 exposed to other treatment, sickexposed to other treatment, sick 14.14[0.66; 302.33]37 -NAMorrow (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2006 1 Tags Adjustment   - No  - No 5.01[0.55; 45.94]4780%NAThomas (Oxcarbazepine) (Controls unexposed, sick), 2021 Morrow (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2006 2 All studiesAll studies 5.01[0.55; 45.94]4780%NAThomas (Oxcarbazepine) (Controls unexposed, sick), 2021 Morrow (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2006 20.550.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 12831

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls 1.60[0.06; 39.70]171 -NAThomas (Oxcarbazepine) (Controls unexposed, sick), 2021 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 4.11[0.23; 74.41]37828%NAThomas (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2021 Morrow (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2006 20.510.01.0